Scientists Explore Vaccinating Bats to Prevent Disease Spillover to Humans

For decades, humanity's pandemic playbook has been reactive: wait for a virus to jump from animals to humans, then scramble to contain it. Now, a growing cohort of scientists is asking a deceptively simple question — what if we could stop the next pandemic before it ever reaches a single human being, by vaccinating the animals that harbor the deadliest viruses on Earth?

Bats, the only mammals capable of true flight, are reservoir hosts for an extraordinary roster of lethal pathogens: Ebola, Marburg, Nipah, Hendra, rabies, SARS-CoV, and potentially SARS-CoV-2 [1][2]. Comprising roughly 20% of all known mammal species — more than 1,400 species worldwide — bats harbor at least 60 zoonotic viruses capable of jumping to humans [3][4]. The resulting diseases have killed tens of thousands of people and caused economic devastation measured in trillions of dollars. The COVID-19 pandemic alone, widely suspected to have originated in horseshoe bats, killed millions and cost the global economy an estimated $16 trillion [5].

The logic is straightforward: if you can immunize the reservoir, you can break the chain of transmission before spillover occurs. But the execution is anything but simple. How do you vaccinate a wild animal that lives in remote caves, flies at night, and numbers in the billions across every continent except Antarctica?

Mosquitoes as Flying Syringes

A new study published March 13, 2026 in Science Advances offers one of the most creative answers yet. Virologist Aihua Zheng and colleagues at the Chinese Academy of Sciences have demonstrated that mosquitoes — which naturally bite bats and are also consumed by insectivorous bat species — can serve as dual-purpose vaccine delivery vehicles [1][6].

The team fed mosquitoes blood laced with genetically engineered vaccines targeting Nipah virus and rabies. The vaccine antigens accumulated in the mosquitoes' bodies and salivary glands. When these mosquitoes subsequently bit bats, or when bats ate the vaccine-laden insects, the animals developed robust antibody responses against both viruses within weeks [1].

The results were striking. When vaccinated bats were later exposed to live rabies virus — normally a death sentence — most survived. Unvaccinated control animals did not [1][6]. Zheng envisions releasing engineered mosquitoes into cave systems where bats roost, using directed air currents at cave entrances to keep the insects contained while allowing bats to come and go freely. "The advantage is if we immunize the population, the transmission of the virus will be decreased or eventually eliminated," Zheng told NPR. The approach, he emphasized, would "not only protect the human but also protect the animals" [1].

As a complementary strategy, Zheng's team also developed an oral rabies vaccine mixed into saline solution. Exploiting bats' attraction to mineral salts, the researchers designed traps that released a salty mist to lure bats to shallow reservoirs containing the vaccine, delivering immunization through drinking [1][6].

The Self-Spreading Vaccine Frontier

While Zheng's mosquito approach represents the newest entry in the field, it builds on nearly a decade of research into an even more ambitious concept: vaccines that spread themselves through animal populations.

There are two main variants. Transferable vaccines are applied as a gel or paste to captured bats' fur. When colony-mates groom the treated individual — a common social behavior, especially among vampire bats — they ingest the vaccine and become immunized themselves [7][8]. Transmissible vaccines go further: they use live, genetically modified viruses that are already endemic to the target species, engineered to carry immunogenic genes from the target pathogen. These vaccine viruses can replicate and spread from animal to animal, theoretically immunizing an entire population from a single inoculation point [7][9].

Daniel Streicker, a disease ecologist at the University of Glasgow, has conducted some of the most advanced field work on transferable vaccines in vampire bat populations in Peru. In experiments across three bat colonies, Streicker's team applied fluorescent biomarkers to captured bats as a proxy for vaccine gel, then tracked how far the substance spread through grooming. The results showed that at least 84% of colony members glowed with the biomarker, indicating that a transferable vaccine could reach immunization levels sufficient for disease control — approximately 2.6 times the coverage achievable with conventional, one-bat-at-a-time vaccination [8][10].

The transmissible approach has shown even more dramatic potential in modeling studies. Researchers examining Desmodus rotundus betaherpesvirus (DrBHV), a virus naturally found in common vampire bats, have modeled its use as a vector for a rabies vaccine. Simulations published in PNAS suggested that inoculating a single bat with a DrBHV-vectored rabies vaccine could immunize more than 80% of an entire colony, reducing the size, frequency, and duration of rabies outbreaks by 50 to 95% [9][11].

Separately, U.S. Geological Survey researchers developed a recombinant raccoon poxvirus vaccine (RCN-MoG) that provided 100% protection against rabies when delivered through the nose and 83% protection when applied topically to big brown bats. Crucially, the vaccine also appeared to block viral shedding in saliva — meaning even vaccinated bats that ultimately succumbed to infection were unlikely to transmit the virus to others [12].

Why Bats Matter: A Catalogue of Catastrophe

The urgency behind these efforts is rooted in a grim epidemiological record. Bat-borne viruses have caused some of the deadliest disease outbreaks in modern history.

Marburg virus, first identified in 1967, carries an average case fatality rate of 50% — and up to 88% in severe outbreaks. It has caused 373 documented human deaths since its discovery, with the most recent major outbreak striking Rwanda in late 2024 [2][13].

Ebola virus, discovered in 1976 in what is now the Democratic Republic of Congo, kills roughly half of those it infects. Across 72 documented outbreaks, filoviruses like Ebola and Marburg have caused more than 17,000 deaths, with more than 90% attributable to these two viruses [2][13].

Nipah virus emerged in Malaysia in 1998, causing 265 cases and 108 deaths in its first outbreak. With a case fatality rate between 40% and 75%, it has repeatedly struck Bangladesh and India and remains on the WHO's priority pathogen list for its pandemic potential [13][14].

SARS-CoV in 2002-2003 infected more than 8,000 people across two dozen countries, killing 774. Its successor, SARS-CoV-2, needs no introduction [13].

Hendra virus has killed four people in Australia since its discovery in 1994, with horses serving as intermediate hosts between bats and humans [13].

And these are just the viruses we know about. Research estimates that an median of 66,280 people are infected with bat SARS-related coronaviruses annually in Southeast Asia alone — most cases likely going undetected [15].

Source: WHO / PMC Systematic Reviews

Data as of Mar 14, 2026CSV

The One Health Equation

The bat vaccination effort sits within a broader intellectual framework known as One Health, which recognizes that human, animal, and environmental health are fundamentally interconnected [16]. The approach has gained significant traction since COVID-19, but advocates argue it still receives far too little investment relative to reactive pandemic response.

Ausraful Islam, a veterinarian and infectious disease specialist at the International Centre for Diarrhoeal Disease Research (icddr,b) in Dhaka, Bangladesh, has studied Nipah virus spillover in South Asia for years. While encouraged by Zheng's research, Islam cautioned that critical questions remain — particularly about how long vaccine-induced immunity persists in wild bat populations and whether large-scale deployment is feasible in diverse environments [1].

There are also lower-tech interventions that have shown promise. In Bangladesh, covering the shaved areas of palm tree trunks and sap collection vessels — preventing contamination with bat urine and saliva — has reduced Nipah virus transmission risk from contaminated date palm sap [16]. In Australia, research has shown that Hendra virus spillovers to horses did not occur when remnant patches of native forest flowered and provided adequate food for flying foxes, suggesting that habitat restoration could be as effective as vaccination in some contexts [16][17].

The Ethics of Ecological Intervention

Not everyone is enthusiastic about releasing engineered biological agents into wild ecosystems. The most pointed concerns surround transmissible vaccines — live viruses designed to spread autonomously through animal populations.

Michael Jarvis, a virologist at the University of Plymouth, has emphasized the need for extreme caution. "Whenever you're dealing with a biological organism that you're potentially thinking of releasing, then you need to err very heavily on the side of caution," he told Quanta Magazine [10]. The core risk is evolutionary: a live vaccine virus, once released, could mutate in unpredictable ways. A poorly designed construct could theoretically evolve to become pathogenic — the precise opposite of its intended purpose [7][10].

Scott Nuismer and James Bull, mathematical and evolutionary biologists at the University of Idaho who have been among the most prominent advocates for self-disseminating vaccines, acknowledge these risks but argue they can be managed through careful design. Their preferred approach uses recombinant vectors — taking a benign virus already circulating in the target species and inserting only a small immunogenic fragment of the target pathogen, rather than using a weakened version of the pathogen itself. This limits the vaccine's ability to revert to virulence [7][10].

No transmissible vaccine has ever been deployed in wildlife to prevent disease transmission to humans or domestic animals [7]. The regulatory frameworks for approving such a release remain largely undefined, existing in a gray zone between veterinary medicine, environmental regulation, and biosecurity governance.

Maria Elena Bottazzi, a vaccinologist at Texas Children's Hospital and Baylor College of Medicine, has pointed to another structural obstacle: funding. Unlike human vaccines, wildlife vaccines offer no clear commercial market. Pharmaceutical companies have little financial incentive to develop products for bats, and public funding for proactive pandemic prevention — as opposed to reactive response — remains chronically underfunded [10]. The PREDICT program, a USAID-funded initiative that monitored emerging viruses in wildlife, was shut down in 2019, just months before COVID-19 emerged [10].

The Road Ahead

The science of bat vaccination is advancing rapidly across multiple fronts simultaneously. Zheng's mosquito-based delivery system, Streicker's transferable gel vaccines, the DrBHV transmissible vaccine platform, and conventional approaches like the RCN-MoG topical vaccine each target different aspects of the problem — different bat species, different pathogens, different ecological contexts.

What they share is a paradigm shift: moving pandemic prevention upstream, to the animal reservoirs where dangerous viruses circulate long before they reach humans. As Zheng's study notes, approximately 60-75% of human infectious diseases originate in animals, with roughly 72% of those tracing back to wildlife [3][4]. Bats, with their unique immune systems, vast species diversity, colonial living habits, and wide geographic range, sit at the epicenter of this threat.

Source: Nature Ecology & Evolution / PNAS / Science Advances

Data as of Mar 14, 2026CSV

The challenges ahead are formidable. Scaling any of these approaches from laboratory proof-of-concept to continent-spanning deployment will require not just scientific breakthroughs but regulatory innovation, sustained funding, and international cooperation — particularly given that the highest-risk bat-human interfaces are concentrated in low- and middle-income countries in South and Southeast Asia, sub-Saharan Africa, and Latin America [15][16].

But the cost of inaction is not hypothetical. Between 1940 and 2004, researchers documented 335 emerging infectious disease events, with more than 60% of zoonotic origin [3]. The next pandemic virus may already be circulating in a bat colony somewhere in the tropics, awaiting the ecological disruption — deforestation, urbanization, wildlife trade — that brings it into contact with a human host.

The question is no longer whether vaccinating bats is theoretically possible. It is whether the world will invest in doing it before the next spillover event forces yet another reactive, catastrophically expensive response.